FFAR4

Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsight

Retrieved on: 
Wednesday, January 17, 2024
Obesity, Merck & Co., MRI, LAS, Weight loss, Fatty liver disease, Type 2 diabetes, Magnetic resonance imaging, Insulin resistance, NASH, FFAR4, Liver, Liver disease, Diabetes, Alcoholic liver disease, Therapy, Hypertension, PPAR, Eli Lilly and Company, Gilead Sciences, Chronic pain, Disease, Inflammation, FASN, AstraZeneca, Novo Nordisk, FXR, Prevalence, CCR5, FGF, Physical examination, Weakness, Bronchial thermoplasty, Cilofexor, Metabolic syndrome, Mitsubishi Tanabe Pharma, Development, NAFLD, Risk, Fibrosis, Fatigue, Dyslipidemia, USD, Non-alcoholic fatty liver disease, Merck, Pharmaceutical industry

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.

Key Points: 
  • LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.
  • According to DelveInsight's analysis, the market size for NASH reached USD 200 million in 2022 in Japan and is expected to grow with a significant CAGR by 2032.
  • DelveInsight's analysis reveals that the overall diagnosed prevalent population of NASH in Japan was reported as 2.5 million in 2022.
  • Among the forecasted emerging therapies, MGL-3196 (Resmetirom) is expected to capture the highest market in Japan by 2032.

Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsight

Retrieved on: 
Wednesday, January 17, 2024
Obesity, Merck & Co., MRI, LAS, Weight loss, Fatty liver disease, Type 2 diabetes, Magnetic resonance imaging, Insulin resistance, NASH, FFAR4, Liver, Liver disease, Diabetes, Alcoholic liver disease, Therapy, Hypertension, PPAR, Eli Lilly and Company, Gilead Sciences, Chronic pain, Disease, Inflammation, FASN, AstraZeneca, Novo Nordisk, FXR, Prevalence, CCR5, FGF, Physical examination, Weakness, Bronchial thermoplasty, Cilofexor, Metabolic syndrome, Mitsubishi Tanabe Pharma, Development, NAFLD, Risk, Fibrosis, Fatigue, Dyslipidemia, USD, Non-alcoholic fatty liver disease, Merck, Pharmaceutical industry

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.

Key Points: 
  • LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.
  • According to DelveInsight's analysis, the market size for NASH reached USD 200 million in 2022 in Japan and is expected to grow with a significant CAGR by 2032.
  • DelveInsight's analysis reveals that the overall diagnosed prevalent population of NASH in Japan was reported as 2.5 million in 2022.
  • Among the forecasted emerging therapies, MGL-3196 (Resmetirom) is expected to capture the highest market in Japan by 2032.

NorthSea Therapeutics to Present ICONA Phase 2b Data as an Oral Late-breaker Session at the 2023 AASLD Liver Meeting

Retrieved on: 
Friday, November 10, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, NST, Arm, FFAR4, Safety, Insulin resistance, NAS, Prevalence, Cirrhosis, Fatty liver disease, Membrane protein, DSM-IV codes, Patient, ICONA, Diabetes, Liver injury, FFAR1, Biomarker, Portsmouth Northsea Swimming Club, AI, NASH, Inflammation, Fibrosis, Pharmaceutical industry, Medical imaging, T2D, Boston

A significant treatment effect size (31.2% placebo adjusted, p=0.007) was observed for the same endpoint in T2D patients.

Key Points: 
  • A significant treatment effect size (31.2% placebo adjusted, p=0.007) was observed for the same endpoint in T2D patients.
  • Based on the highly favorable response (both histological and non-invasive biomarkers) to therapy in T2D patients, NorthSea will pursue a registrational development path for Icosabutate in NASH patients with T2D.
  • What is less well known is that subjects with both diabetes and NASH have a high prevalence of underlying significant liver fibrosis.
  • Patients were randomized 1:1:1 to receive once-daily, oral Icosabutate 300mg, Icosabutate 600mg or placebo for 52 weeks.

Icosabutate Latest Phase 2b Interim Data Show Significant Decreases in NASH and Fibrosis Biomarkers Independent of Fibrosis Stage and Disease Severity

Retrieved on: 
Tuesday, November 16, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Histology, Population, Biomarker, Hepatitis, NST, Non-alcoholic fatty liver disease, Therapy, Cirrhosis, BGV, Diabetes, Liver, Inflammation, Seed, NAFLD, Lists of diseases, HIV disease progression rates, Association, ICONA, ALT, SEFA, Dyslipidemia, Portsmouth Northsea Swimming Club, NASH, NSV, Membrane protein, FFAR4, Sofinnova, Abstract, Liver transplantation, Hypertriglyceridemia, Fibrosis, Adult, Patient, Squamous cell carcinoma, Chronic liver disease, Liver failure, Obesity, Pharmaceutical industry, Dietary supplement, NASH, Icosabutate, NorthSea Therapeutics, NASH, ICOSABUTATE, NORTHSEA THERAPEUTICS

Rob de Ree, Chief Executive Officer at Northsea added, Northsea is committed to developing novel therapies for patients with life-threatening liver diseases.

Key Points: 
  • Rob de Ree, Chief Executive Officer at Northsea added, Northsea is committed to developing novel therapies for patients with life-threatening liver diseases.
  • Title: Icosabutate, a novel oral free fatty acid 4 (FFAR4) agonist, significantly decreases biomarkers of NASH and fibrosis independent of disease severity (Abstract #1915)
    The presentations will also be made available on the Northsea Therapeutics website ( www.northseatherapeutics.com/publications ) after the data has been presented at the meeting.
  • NASH is a chronic liver disease characterized by liver inflammation and fibrosis and represents a more advanced stage of non-alcoholic fatty liver disease (NAFLD).
  • The icosabutate phase 2b ICONA NASH trial is scheduled to readout in the first quarter of 2023.